Improving beta‐cell secretory function and glycaemia in young‐onset type 2 diabetes: A pilot, 12‐month, randomized trial of a novel, continuous glucose monitor‐guided, rapid treatment intensification strategy incorporating empagliflozin and liraglutide

The authors declare that they have no competing interests. The peer review history for this article is available at https://publons.com/publon/10.1111/dom.14621. The data that support the findings of this study are available from the corresponding author upon reasonable request. Appendix S1. Supporting Information. Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.